Contagion Live: Targeting Lung Blood Vessel Inflammation in COVID-19 Patients
UC cardiologist discusses use of razuprotafib to lessen blood vessel inflammation
Richard Becker, MD, director of the UC Heart, Lung and Vascular Institute, was interviewed by a reporter for Contagion Live about a new phase 2 clinical trial UC and UC Health are conducting using the drug razuprotafib, to lessen inflammation of the blood vessels in COVID-19 patients. Razuprotafib activates a key pathway for stabilizing blood vessels in the lungs and may prevent or treat respiratory distress in COVID-19 patients. Becker, also a UC Health cardiologist, and Duncan Hite, a professor in the UC College of Medicine, and medical director of critical care at UC Health, are overseeing the trial using razuprotafib at UC. The drug is being used as a part of clinical trial in 20 sites across the nation.
Listen to the Contagion Live interview online.
Learn more about the research involving Dr. Becker and Dr. Hite.
Related Stories
More young adults are having strokes than three decades ago
September 23, 2026
A University of Cincinnati-led study published in the journal Neurology found that strokes among adults ages 20 to 54 nearly doubled over almost three decades, even as short-term survival after stroke improved.
UC part of $18 million initiative to expand behavioral health workforce in Ohio
September 23, 2026
The University of Cincinnati is participating in a new $18 million statewide scholarship program, as Cleveland.com recently reported, to address critical shortages of mental health and substance use treatment providers across Ohio.
Is Cincinnati building new homes fast enough?
September 22, 2026
Gary Painter, professor and academic director of the Real Estate Center at UC's Lindner College of Business, offers comments on affordability issues in Cincinnati.